State of Medtech

210. Exits: $10.8B Exit to Merck with Prometheus Biosciences CEO Mark McKenna


Listen Later

This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.


00:00 Introduction and Welcome

00:32 Guest Introduction: Mark McKenna

00:42 The Prometheus Acquisition by Merck

01:01 Mark's Career Journey and Decision to Join Prometheus

04:55 Challenges and Strategies in the First Year

06:48 Key Inflection Points and Fundraising

08:58 Building a Competitive and Sustainable Company

13:32 Navigating Market Challenges and Competition

19:33 Reflections and Leadership Insights

21:32 Future of Biotech and Industry Concerns

24:42 Conclusion and Farewell


For limited time only - Get the Medical Sales Network Effects Program for 60% off https://salesnetworkeffectsprogram.mykajabi.com/offers/FV2MG8sK?coupon_code=PODCAST2024

Follow The State of MedTech on:

  • ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠
  • ⁠⁠⁠⁠Instagram⁠⁠⁠⁠
  • TikTok
  • ⁠⁠⁠⁠Twitter⁠⁠⁠⁠
  • ⁠⁠⁠⁠Facebook⁠⁠⁠⁠

Follow Omar M. Khateeb on

  • ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠
  • ⁠⁠⁠⁠Instagram⁠⁠⁠⁠
  • TikTok
  • ⁠⁠⁠⁠Twitter⁠⁠⁠⁠
  • ⁠⁠⁠⁠Facebook⁠⁠
...more
View all episodesView all episodes
Download on the App Store

State of MedtechBy State of Medtech